Biodexa Pharmaceuticals (BDRX) Net Margin (2015 - 2021)

Biodexa Pharmaceuticals (BDRX) has 5 years of Net Margin data on file, last reported at 786.03% in Q4 2021.

• For the quarter ending Q4 2021, Net Margin rose 21602647.0% year-over-year to 786.03%; the trailing twelve-month figure through Dec 2021 stood at 3680.05% (up 500.0% YoY), and the FY2023 full-year result was 2069.82%, down 163248.0% from the prior year.
• Net Margin rose to 786.03% in Q4 2021, from 216812.5% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 411.74% in Q4 2019 to a low of 228725.0% in Q3 2020.
• A 3-year average of 111683.82% and a median of 108799.27% in 2020 frame the typical range for Net Margin.
• Across the five-year window, Net Margin sank 21640076 bps in 2020 and surged 21602647 bps in 2021, its largest moves.
• Tracing BDRX's Net Margin over 3 years: stood at 411.74% in 2019, then sank by 52558 bps to 216812.5% in 2020, then soared by 100 bps to 786.03% in 2021.
• Business Quant data shows BDRX's Net Margin at 786.03% in Q4 2021, 216812.5% in Q4 2020, and 228725.0% in Q3 2020.